Skip to content

Nurix Therapeutics, Inc. NRIX Lease Liability Payments - Due Year Three

Lease Liability Payments - Due Year Three at other companies

Nuvation Bio logo
Nuvation BioNUVB
$1.22M+613%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$1.54M+9.8%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$2.95M+26.6%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Revenue$6.3M-66.1%
Operating income-$92.5M-47.1%
Net income-$87.2M-54.7%
EPS (diluted)-$0.79-17.9%

Balance sheet

See full
Cash & equivalents$72.2M-6.1%
Total debt$58.7M+120%
Total equity$480.9M0.0%
Total assets$636.1M+3.4%

Cash flow

See full
Operating cash flow-$71.9M-17.7%
CapEx$1.0M-70.0%
Free cash flow-$73.0M-13.0%

Valuation

See full
Market cap$1.95B+40.1%
Enterprise value$1.94B+45.1%
P/S27.2×+2.5×

Profitability

See full
Operating margin-439.3%+35.3pp
Net margin-411.4%+52.7pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-61.4%-2.5pp
Debt / equity0.1×+0.1×
Current ratio-0.3×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree.

The official record: Nurix Therapeutics, Inc.’s 10-K, filed January 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nurix Therapeutics, Inc.'s lease liability payments - due year three.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nurix Therapeutics, Inc.'s lease liability payments - due year three?
Nurix Therapeutics, Inc. (NRIX) reported lease liability payments - due year three of $13.46M in Q3 2025.
What does lease liability payments - due year three mean?
The contractual cash obligations for operating and finance leases due in the third year following the balance sheet date. This metric helps in mapping out the long-term fixed cost profile of the company. It is essential for evaluating the sustainability of lease-related cash outflows over a multi-year horizon.